Abstract 2084P
Background
CV mortality is the leading preventable cause of death in cancer patients. Understanding the timing and quantifying the magnitude of CV mortality can facilitate strategies to reduce mortality.
Methods
Surveillance, Epidemiology, and End Results (SEER) database (2004-2018) were queried to obtain CV mortality (defined as deaths due to heart diseases, hypertension, cerebrovascular diseases, atherosclerosis, aortic aneurysm, and dissection) in metastatic cancer patients. Standardized mortality ratios (SMRs) were calculated (observed deaths from each category divided by the expected number of deaths in the age-matched US population for the same period). SMR was presented by latency periods of <2, 2-5, and >5 years after the initial diagnosis of metastatic cancer and stratified by age (<50 years, 50-70 years, >70 years), race (White, Black, Asian/Pacific Islander, Native American), and ethnicity (Hispanic, Non-Hispanic).
Results
This analysis included 914,804 metastatic cancer patients. Overall, the risk of CV death was highest <2 years of initial diagnosis (SMR: 2.47, 95% CI: 2.35-2.58) compared to population who died 2-5 years (1.22, 1.17-1.27) and 5>years (1.11, 1.03-1.17) after the initial diagnosis. In terms of different subgroups, younger population (age <50 years) observed the highest risk of CV mortality within < 2 years (8.84, 7.5-10.4) except for prostate cancer, where the risk of cardiovascular death becomes highest at >5 years after diagnosis. Similarly, regarding race, Native Americans had the highest risk of CV mortality (6.44, 4.86-8.54), which remained consistent across different cancers. There was significant increase in observed mortality in Hispanic (2.93, 2.62-3.28) and Non-Hispanic (2.43, 2.31-2.55) population. The mortality risk by ethnicity remained consistent with latency periods of <2, 2-5, and > 5years after the initial diagnosis of metastatic cancer.
Conclusions
Metastatic cancer patients who are younger or those who are Native Americans have the highest CV mortality, especially <2 years of initial diagnosis of metastatic disease. Targeted cardio-oncological strategies should be aimed at improving CV mortality in patients who are at highest risk of deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.B. Riaz.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06